print small

Participating Countries:

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Estonia

Finland

France

Germany

Greece

Iceland

Ireland

Israel

Italy

Macedonia

Malta

Netherlands

Poland

Portugal

Romania

Serbia

Spain

Sweden

Switzerland

Turkey

United Kingdom

Cost is supported by the EU Framework Programme Horizon 2020
 
8/7/2016 (Added to site)
Author(s): António O. L. Évora, Ricardo A. E. Castro, Teresa M. R. Maria, M. Ramos Silva, J. H. ter Horst, João Canotilhob and M. Ermelinda S. Eusébioa

Co-crystals of diflunisal and isomeric pyridinecarboxamides – a thermodynamics and crystal engineering contribution†

Journal: CrystEngComm, 2016,18, 4749-4759
DOI: DOI: 10.1039/c6ce00380j

Co-crystals have been the subject of intense research in the last decade, due to their great potential for practical applications in several domains, especially where active pharmaceutical ingredients, APIs, are concerned. Pharmaceutical co-crystals combining an API and an acceptable co-former, have the potential for enhancing the physical properties of the API by impacting its solubility, stability, oral bioavailability and processability, without compromising its biological function.

 

Co-crystals of diflunisal and isomeric pyridinecarboxamides – a thermodynamics and crystal engineering contribution†

 
 
 


Project Office

Working groups


COST – what's in it for researchers?



Subscribe to newsletter

This cost action is hosted by the ABCRF, University College Cork, Ireland